Last reviewed · How we verify

Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C. — Portfolio Competitive Intelligence Brief

Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C. pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
silicon gel silicon gel marketed Topical scar treatment / silicone-based dermatological product Dermatology
pirfenidone 8% gel pirfenidone 8% gel phase 3 Antifibrotic agent TGF-β signaling pathway; fibroblast proliferation Dermatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Hospices Civils de Lyon · 1 shared drug class
  2. Merck KGaA, Darmstadt, Germany · 1 shared drug class
  3. Shanghai Zhongshan Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.:

Cite this brief

Drug Landscape (2026). Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fundaci-n-nacional-para-la-ense-anza-y-la-investigaci-n-de-la-dermatolog-a-a-c. Accessed 2026-05-17.

Related